Lixte Biotechnology Holdings Inc
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Undervalued ASX share searches for cost savings
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,868.20 | 33.10 | -0.37% |
| CAC 40 | 8,022.69 | 29.82 | -0.37% |
| DAX 40 | 24,130.14 | 32.51 | -0.13% |
| Dow JONES (US) | 48,057.75 | 497.46 | 1.05% |
| FTSE 100 | 9,655.53 | 13.52 | 0.14% |
| HKSE | 25,540.78 | 106.55 | 0.42% |
| NASDAQ | 23,654.15 | 77.67 | 0.33% |
| Nikkei 225 | 50,602.80 | 52.30 | -0.10% |
| NZX 50 Index | 13,424.00 | 52.94 | 0.40% |
| S&P 500 | 6,886.68 | 46.17 | 0.67% |
| S&P/ASX 200 | 8,579.40 | 31.70 | -0.37% |
| SSE Composite Index | 3,900.50 | 9.03 | -0.23% |